Correlation analysis of serum thyroid stimulating hormone with acute cerebrovascular disease

• Published in: European journal of medical research Vol. 24; no. 1; p. 35
• Main Authors: Zhu, Jian, Chen, Ming, Li, Nan, Yang, Shaoling, Xu, Lu, Wang, Yanru, Li, Hong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 24.10.2019; BioMed Central; BMC
• Subjects: Acute cerebrovascular disease; Acute Disease; Aged; Biomarkers - blood; Brain hemorrhage; Case-Control Studies; Cerebral hemorrhage; Cerebral infarction; Cerebrovascular disorders; Cerebrovascular Disorders - blood; Cerebrovascular Disorders - diagnosis; Complications and side effects; Diagnosis; Female; Follow-Up Studies; Glycoproteins; Health aspects; Hemorrhage; Hormones; Humans; Male; Methods; Pituitary hormones; Prognosis; ROC Curve; Serologic tests; Severity; Severity of Illness Index; Thyroid gland; Thyroid hormones; Thyroid stimulating hormone; Thyrotropin; Thyrotropin - blood; China; Cerebral infarction; Thyroid stimulating hormone; Severity; Prognosis; Acute cerebrovascular disease; Cerebral hemorrhage
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-019-0395-4

Acute cerebrovascular disease (ACVD) could cause abnormal metabolism of thyroid hormones (TH), mostly represented as a euthyroid sick syndrome or low T3 syndrome. However, the changes in serum thyroid-stimulating hormone (TSH) are controversial. The aim of this study is to investigate the clinical significance of TSH alteration in patients with ACVD. Patients with ACVD admitted in our hospitals between January 2013 and September 2017 were enrolled in this study (n = 245, including 176 cerebral infarctions and 69 cerebral hemorrhages). Their thyroid hormones were measured and compared with healthy individuals (n = 75). The correlation of TSH with severity and prognosis of ACVD were analyzed by receiver operating characteristic curve. Serum TSH in ACVD group was higher than the control group (1.64 ± 1.08 vs. 1.26 ± 0.36 μIU/mL, P < 0.05). The TSH levels in intermediate and severe patients with ACVD were higher than in mild patients (1.72 ± 1.18 vs. 2.71 ± 0.93 vs. 1.02 ± 0.47 μIU/mL, P < 0.05). Receiver Operating Characteristic curve (ROC) of TSH in determining the severity of patients were 0.863 (Area under the curve, AUC), 1.496 μIU/L (optimal threshold), 76.5% (sensitivity) and 87.3% (specificity). TSH levels in improved and unchanged groups were significantly higher than the primarily healing group (2.27 ± 1.11 vs. 2.88 ± 1.07 vs. 0.86 ± 0.46 μIU/mL, P < 0.05). ROC of TSH in determining the prognosis of patients was 0.910 (AUC), 1.681 mIU/L (optimal threshold), 79.8% (sensitivity) and 90.5% (specificity) correspondingly. Since elevated TSH in ACVD patients affects the outcome of thyroid function evaluation, it is preferable to re-check after the acute period. A correlation between a high TSH level and the severity and prognosis of ACVD was detected, but the mechanism of this correlation needs to be further studied.